Alpha 2-adrenoceptors do not regulate catecholamine secretion by bovine adrenal medullary cells: a study with clonidine.
Experiments have been performed with perfused bovine adrenal glands, with freshly isolated chromaffin cells, and with chromaffin cells maintained in tissue culture to investigate the suggestion that there are alpha-adrenoceptors present which regulate catecholamine secretion. Only one set of observations has lent support to this suggestion: the rather specific alpha 2-adrenoceptor agonist clonidine inhibits catecholamine secretion evoked by the physiological secretagogue, acetylcholine, and by the related nicotinic agonists, carbachol and nicotine. All other observations detract from the suggestion. Other alpha-adrenoceptor agonists (noradrenaline, adrenaline, tramazoline, phenylephrine, and alpha-methyl-noradrenaline) are virtually ineffective at inhibiting secretion evoked by carbachol. In addition, the alpha-adrenoceptor antagonists phentolamine, phenoxybenzamine, and yohimbine not only fail to enhance the secretion of catecholamines evoked by carbachol but also fail to offset the inhibitory action of clonidine. The data suggest that functional alpha 2-adrenoceptors of the classical type are not present upon bovine chromaffin cells and that, in this tissue, clonidine must act in some other way. In the bovine adrenal medullary chromaffin cell clonidine probably acts at the nicotinic receptor because it does not reduce catecholamine secretion evoked by depolarizing concentrations of potassium or veratridine but does reduce the carbachol-evoked influx of 22Na that can be measured in the presence of tetrodotoxin and ouabain and which probably reflects entry through the nicotinic channel. Furthermore, clonidine can abolish, in reversible fashion, the acetylcholine-activated inward current determined with patch-clamp.
Powis
D A
DA
Baker
P F
PF
D000313:Adrenal Medulla / Q000187:drug effects / Q000378:metabolism*; D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D002217:Carbachol / Q000494:pharmacology; D002395:Catecholamines / Q000378:metabolism*; D002417:Cattle; D002837:Chromaffin Granules / Q000378:metabolism; D003000:Clonidine / Q000494:pharmacology*; D004088:Dihydroergotoxine / Q000378:metabolism; D066298:In Vitro Techniques; D008024:Ligands; D010646:Phentolamine / Q000494:pharmacology; D011188:Potassium / Q000494:pharmacology; D011942:Receptors, Adrenergic, alpha / Q000032:analysis / Q000502:physiology*; D011978:Receptors, Nicotinic / Q000187:drug effects; D012964:Sodium / Q000378:metabolism; D014316:Tritium; D014701:Veratridine / Q000494:pharmacology
D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D002395:Catecholamines; D008024:Ligands; D011942:Receptors, Adrenergic, alpha; D011978:Receptors, Nicotinic; D014316:Tritium; D004088:Dihydroergotoxine; D014701:Veratridine; D002217:Carbachol; D012964:Sodium; D003000:Clonidine; D011188:Potassium; D010646:Phentolamine